Konstantinos Tziomalos, Asterios Karagiannis, Dimitri P. Mikhailidis and Vasilios G. Athyros Pages 3115 - 3123 ( 9 )
Treatment with statins represents an essential component both of primary and secondary cardiovascular prevention strategies. However, a proportion of patients cannot reach low-density lipoprotein cholesterol (LDL-C) targets with the highest tolerable dose of a potent statin or is intolerant to statins. Several treatment options are available for these patients. Colesevelam is a relatively new bile acid sequestrant that decreases serum LDL-C levels. Moreover, colesevelam improves glycemic control and seems to be well-tolerated, at least in short-term studies. Therefore, colesevelam seems to be a useful tool for the management of high-risk patients who cannot achieve LDL-C targets with monotherapy with a potent statin.
Colesevelam, statin intolerance, glycemic control, multifactorial intervention, type 2 diabetes mellitus.
, , , AHEPA University Hospital, 1 Stilponos Kyriakidi street, 546 36, Thessaloniki, Greece.